Subcutaneous dupilumab andmometasone furoate nasal spray for chronic rhinosinusitiswith polyps

Keyphrases

• Polyps 100%
• Dupilumab 100%
• Nasal Spray 100%
• Furoate 100%
• Least Mean Square 71%
• High-score 57%
• Nasal Polyposis 42%
• Chronic Sinusitis 42%
• Placebo 28%
• Sino-Nasal Outcome Test 28%
• Sense of Smell 28%
• University of Pennsylvania Smell Identification Test (UPSIT) 28%
• Nasal Polyps 28%
• Mometasone Furoate Nasal Spray 28%
• Lund-Mackay Score 28%
• Intranasal Corticosteroids 28%
• United States 14%
• Placebo Groups 14%
• Atopic Dermatitis 14%
• Headache 14%
• Interleukin-13 (IL-13) 14%
• Computed Tomography 14%
• Between-group 14%
• Quality of Life 14%
• T Helper 2 14%
• Interleukin-4 (IL-4) 14%
• Treatment Duration 14%
• Asthma 14%
• Computed Tomography Score 14%
• T-cell Mediated 14%
• Nasopharyngitis 14%
• United Europe 14%
• Loading Dose 14%
• Randomized Double-blind Placebo-controlled Parallel-group Study 14%
• Injection Site Reaction 14%
• Mometasone 14%
• Minimal Clinically Important 14%
• Nasal Polyp Score 14%
• Comorbid Asthma 14%

Medicine and Dentistry

• Polyp 100%
• Nasal Spray 100%
• Dupilumab 100%
• Nasal Polyp 85%
• Least Square Analysis 71%
• Placebo 57%
• Chronic Sinusitis 42%
• Computer Assisted Tomography 28%
• Mometasone Furoate 28%
• Headache 14%
• Atopic Dermatitis 14%
• Interleukin 13 14%
• Quality of Life 14%
• Asthma 14%
• Treatment Duration 14%
• Patient with Asthma 14%
• Rhinopharyngitis 14%
• Interleukin 4 14%
• Loading Drug Dose 14%
• Injection Site Reaction 14%
• T Helper 2 Cell 14%
• Diseases 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Polyp 100%
• Nasal Spray 100%
• Dupilumab 100%
• Nose Polyp 85%
• Placebo 57%
• Chronic Sinusitis 42%
• Asthma 28%
• Mometasone Furoate 28%
• Headache 14%
• Rhinopharyngitis 14%
• Interleukin 4 14%
• Interleukin 13 14%
• Atopic Dermatitis 14%
• Injection Site Reaction 14%
• Diseases 14%